Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture

BMJ Case Reports

Volumn , Issue , 2014, Pages

  O'Neill, Barry James ^a   O'HEireamhoin, Sven ^a   Morrissey, David I ^a   Keogh, Peter ^a  

^a Stroke and Hypertension Unit   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ACCIDENT; ADULT; ARTICLE; BONE RADIOGRAPHY; BONE SCREW; CASE REPORT; COLLAPSE; DEVICE REMOVAL; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; INTRAMEDULLARY NAIL; LEG PAIN; MIDDLE AGED; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHYSIOTHERAPY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTHESIS FAILURE; REHABILITATION CARE; SURGICAL APPROACH; TRENDELENBURG TYPE GAIT; UNSTEADY GAIT;

EID: 84898647254     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-203519     Document Type: Article

References (23)

1. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the alendronate phase III osteoporosis treatment study group. N Engl J Med 1995;333: 1437-43.
2. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal oestoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85: 3109-15.
3. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000;85: 4118-24. (Pubitemid 32055362)
4. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343: 604-10. (Pubitemid 30659471)
5. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90: 1294-301. (Pubitemid 40463979)
6. Wee JL, Sathappan SS, Yeo MS, et al. Management of gamma nail breakage with bipolar hemi-arthroplasty. Singapore Med J 2009;50:e44-7.
7. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009;91-A: 2556-61.
8. Kwek EB, Goh SH, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39: 224-31.
9. Yoon RS, Beebe KS, Benevenia J. Prophylactic bilateral intramedullary femoral nails for bisphosphonate-associated signs of impending subtrochanteric hip fracture. Orthopaedics 2010;33: 267-70.
10. Somford MP, Draijer FW, Thomassen BJ, et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Min Res 2009;24: 1736-40.
11. Schmidt A, Rutledge SJ, Endo N, et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate Proc Natl Acad Sci USA 1996;93: 3068-73. (Pubitemid 26114364)
12. Sato M, Grasser W, Endo N, et al. Bisphosponate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88: 2095-105.
13. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006;296: 2927-38. (Pubitemid 46021497)
14. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15: 613-20. (Pubitemid 30174014)
15. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28: 524-31. (Pubitemid 32416465)
16. Little DG, Ramachandran M, Schideler A. The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 2007;89-B: 425-33. (Pubitemid 46851119)
17. Fleisch H. Can bisphosphonates be given to patients with fractures? J Bone Miner Res 2001;16: 437-40. (Pubitemid 32173357)
18. Solomon DH, Hochberg MC, Mogun H, et al. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int 2009;20: 895-901.
19. Bosemark P, Isaksson H, McDonald MM, et al. Augmentation of autologous bone graft by a combination of bone morphogenic protein and bisphosphonate increased both callus volume and strength. Acta Orthop 2013;84: 106-11.
20. Black DM, Kelly MP, Genant HK, et al. Fracture intervention trial steering committee; HORIZON pivotal fracture trial steering committee. bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362: 1761-71.
21. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305: 783-9.
22. Hampson G, Fogelman I. Clinical role of bisphosphonate therapy. Int J Womens Health 2012;4: 455-69.
23. Murphy CG, O'Flanagan S, Keogh P, et al. Subtrochanteric stress fracture in patients on oral bisphosphonate therapy: an emerging problem. Acta Orthop Belg 2011;77: 632-7.